A group of investment companies, including TPG growth and GIC-backed entities, have submitted a formal notice to the Competition Commission of India (CCI).
The proposed transaction includes several major players: Waverly Pte. Ltd., TPG Growth v SF Markets Pte. Ltd., TPG Growth III SF PTE. Ltd., Asia Healthcare Holdings Pte. Ltd. (Ahh Singapore), Rhea Healthcare Private Limited, Asia Healthcare Advisory Holdings LLP, and the Asian Institute of Nephrology and Urology Private Limited (AINU). Supported by Global Investment Giants TPG Inc. and GIC Ventures, these companies play an important role in shaping the private health market in India.
According to CCI filings, the transaction includes multiple financial and structural adjustments. Waverly subscribes to AHH Singapore’s common stock and Class F redemptionable preferred stock, while Growth V and Growth III receive minority rights in AHH Singapore, Rare and Ainu. The reorganization also includes reclassification of existing Class e redemptive preferred stocks, with Growth V and Waverly holding separate categories of these stocks.
An important part of the transaction is the transfer of the Ainu from AHH Singapore to Rhea, and then Rhea issues shares to Ahh Singapore as a consideration for transfer. Additionally, mechanisms have been put in place to increase Waverly’s stockholdings in AHH Singapore over the long term.
Restructuring is classified as a acquisition of shares and voting rights under sections 5(a) and 5(b) of the Competition Act 2002. The entities involved operate in major healthcare segments such as maternal and child healthcare, urology, and dialysis. and kidney transplants.
Ahh Singapore, jointly managed by TPG and GIC, has long-term investments in multiple health services in various states and coalition regions of India.
TPG Growth III and V serve as investment funds managed by TPG Inc. TPGInc. is a NASDAQ registered private equity company specializing in technology, healthcare, consumer and financial services.
Waverly is a wholly subsidiary of GIC Ventures, part of Singapore’s sovereign wealth fund managed by GIC Special Investment Private Limited. Co-engineering with AHH Singapore will strengthen its position in the healthcare sector in India and ensure long-term strategic investment in specialized hospitals.
Companies argue that restructuring is an internal transaction between affiliated entities and does not have a significant impact on market competition. The filing also provides overlap analysis of Indian health care services, covering primary care in duplicate cities, secondary and tertiary care for professional procedures, and Quaternary care across the country. The transaction did not create a significant negative impact on competition (AAEC), so the applicants required that CCI be open to the definition of the relevant market.
If CCI grants approval, this restructuring will optimize the ownership structure of TPG and GIC-supported companies in India’s growing health sector and strengthen their investment strategies. Regulatory reviews are closely monitored by industry analysts. The results are because it could set precedents for future investment and integration trends in the country’s private health environment. Hindu business line
